

**MISSISSIPPI DIVISION OF MEDICAID  
DRUG UTILIZATION REVIEW (DUR) BOARD  
MINUTES OF THE NOVEMBER 21, 2013 MEETING**

<b>DUR Board Members:</b>	<b>Present</b>	<b>Absent</b>
Allison Bell, Pharm.D.	✓	
James R. "Beau" Cox, Pharm.D. (Co-Chair)	✓	
Logan Davis, Pharm.D.	✓	
Lee Greer, M.D.		✓
Antoinette M. Hubble, M.D.		✓
Sarah Ishee, Pharm.D.	✓	
Cherise McIntosh, Pharm.D.	✓	
Jason Parham, M.D.	✓	
Bobby Pactor, M.D.		✓
Sue Simmons, M.D.		✓
Dennis Smith, R.Ph. (Chair)	✓	
Cynthia Undesser, M.D.		✓
<b>Total</b>	<b>7</b>	<b>5</b>

**Also Present:****DOM Staff:**

Judith Clark, R.Ph., DOM Pharmacy Bureau Director; Terri Kirby, R.Ph., DOM Clinical Pharmacist; Tamiko Young; Carmen Robinson; Andrea McNeal, PI; Sue Reno, PI; Wil Ervin

**MS-DUR Staff:**

Kyle Null, Pharm.D., Ph.D., Clinical Director; Ben Banahan, Ph.D., Project Director, Ruchit Shah, Graduate Research Assistant

**Xerox Staff:**

Leslie Leon, Pharm.D.

**Visitors:**

Dan Barbera, Lilly; Ed MacMillan, Abbott; Melanie Vanderpool, Astellas; John Kirby, Sanofi; Tim Hambacher, Otsuka; Teri Breidenbach, Pfizer, Roger Grozinger, BMS; Adam Reno, Walgreens; Jeff Stockard, Walgreens

**Call to Order:** Mr. Dennis Smith, Chairman of the Board, called the meeting to order at 2:00pm.

Dr. McIntosh is expected to arrive late, therefore approval of minutes was deferred until her arrival. Ms. Clark, Pharmacy Director, represented DOM for Ms Hardwick, DUR Coordinator, who was unable to attend.

**Resource Utilization Review:**

Dr. Null discussed changes in the Resource Utilization report. MS-DUR will be adding enrollment data and other "movers and shakers" reports in the following months. Mr. Smith asked if a % change column

could be added. MS-DUR is planning to add % change and share in class. It was also suggested that the report contain a change in utilization comparison to the prior quarter and possibly the prior year.

**Pharmacy Program Update:**

Ms. Clark noted folders were provided containing recent provider notices from the Division of Medicaid. She highlighted a few topics: (1) pharmacy permit renewal time and the need for pharmacy permit renewals to be sent to Xerox, (2) a small number of beneficiaries will be migrating from CHIP to Medicaid, (3) the Preferred Drug List will be updated effective 1/1/2014, (4) OTC formulary items will no longer be covered for long-term care, (5) a new pharmacy standard prior authorization form will be available at the first of 2014, (6) the new Federal mandate that any prescriber for Medicaid covered prescription must be written by a provider enrolled in Medicaid, and (7) DOM will start covering the Zoster vaccine for enrollees 60 and over through the point-of-sale (POS) and medical benefits. Ms. Clark also noted that the Drug Information Service at UMMC will be assisting with the prior authorization process.

Ms. Clark called attention to the Center for Mississippi Health Policy publication and the mention of Division of Medicaid and the Prescription Monitoring Program. Dr. Null briefed board on work with PQA and upcoming studies to be reviewed at the February Board Meeting.

Ms. Clark announced that a provider notice will be coming out soon about Ciprodex age edits and Pulmicort. She also noted that the DOM is working with the MSCAN program to develop a unified preferred drug list. She added that the DOM also wants to develop uniformity as to what drugs are covered through pharmacy or medical only, which is already being done in several other states. Ms. Clark concluded the pharmacy program update by pointing out that GHS has already worked with Texas and West Virginia to accomplish PDL uniformity with the managed Medicaid plans.

**New Business:***Utilization of Elidel and Protopic*

Dr. Null reported on the utilization of Elidel and Protopic due to unusual days supply reported on claims by pharmacies, noting that Magnolia has 1 gm/day and United Healthcare has 2 gr/day limits on these products. A discussion ensued regarding the placement of a quantity limit on Elidel and Protopic, but the general consensus was reached that no action be taken at this time.

*Diabetic Supply DME Claims Analysis*

Dr. Banahan reviewed insulin supply issues related to reimbursement being limited to DME. Several Board members commented that results were very alarming, suggesting that the analysis clearly was in favor of DOM covering diabetic supplies at the POS. The consensus of the Board members was that the current policy should be changed to allow coverage of diabetic supplies at the POS. The vote was deferred until Dr. McIntosh arrived. Ms. Clark recommended that a CE article be prepared jointly by MS-DUR, the P&T Committee, and the DUR Board.

*Adherence to Diabetes Medications*

Dr. Null reviewed a report on adherence to diabetic medications. He reviewed the issue of case-mix adjustments when reviewing outcomes-oriented quality measures. Dr. Ishee pointed out that DUR should look at adherence to more expensive antidiabetic agents since these are less likely to be dropped or switched to cash when prescription limit is reached.

Dr. McIntosh arrived at 3:02pm. The following items were reviewed and votes taken.

Dr. Parham made a motion that the recommendation from MS-DUR regarding reimbursement policy for insulin supplies be approved as printed in packet. Motion was seconded by Dr. Bell. All voted in favor of the motion.

Mr. Smith asked for a motion to accept the minutes from the meeting of August 15, 2013. Dr. Cox made a motion to accept the minutes with a second from Dr. Davis. All voted in favor of the motion.

*Exceptions Monitoring*

Dr. Null reviewed exceptions criteria recommendations. All exceptions monitoring criteria reviewed at this meeting were from FDA recommended safety warnings and labeling changes for things MS-DUR can monitor in a meaningful way. Dr. Ishee recommended accepting the exceptions monitoring criteria as a block vote, which was seconded by Dr. McIntosh.

**Other Business:**

Dr. Banahan reviewed the process of ad hoc projects and encouraged the Board to recommended ad hoc projects.

**Next Meeting Information**

Mr. Smith announced that the next meeting date is February 13, 2014 at 2:00p.m. and thanked everyone for making the effort to attend the DUR Board meeting in order to have a quorum. Dr. Null noted that this is one week earlier than normal due to the ADURS conference. The meeting adjourned at 3:21pm.

Submitted,  
Evidence-Based DUR Initiative, MS-DUR